Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
UBS
Harvard Business School
McKesson
McKinsey
Argus Health
Novartis
Medtronic
Citi
Federal Trade Commission

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,962,908

« Back to Dashboard

Which drugs does patent 6,962,908 protect, and when does it expire?

Patent 6,962,908 protects FEMTRACE and is included in one NDA.

This patent has eleven patent family members in ten countries.
Summary for Patent: 6,962,908
Title: Oral pharmaceutical products containing 17 .beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation
Abstract:A pharmaceutical dosage unit for oral administration to a human female comprising a therapeutically effective amount of 17.beta.-estradiol-3-lower alkanoate, most preferably 17.beta.-estradiol-3-acetate, and a pharmaceutically acceptable carrier is disclosed. Also disclosed is a method for treating a human female in need of 17.beta.-estradiol and a contraceptive method by oral administration of the pharmaceutical dosage unit and a method of preparing a pharmaceutical composition that may be used to form the pharmaceutical dosage unit of the invention.
Inventor(s): Aloba; Oluwole T. (Morristown, NJ), deVries; Tina M. (Long Valley, NJ)
Assignee: Warner Chilcott Company Inc. (Fajardo, PR)
Application Number:10/023,748
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 6,962,908

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-001 Aug 20, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-002 Aug 20, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-003 Aug 20, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,962,908

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,572,779 Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation ➤ Try a Free Trial
7,799,771 Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,962,908

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
New Zealand 532491 ➤ Try a Free Trial
Norway 20042565 ➤ Try a Free Trial
Mexico PA04006057 ➤ Try a Free Trial
Japan 2005517673 ➤ Try a Free Trial
Israel 160797 ➤ Try a Free Trial
European Patent Office 1461043 ➤ Try a Free Trial
China 1273141 ➤ Try a Free Trial
China 1564689 ➤ Try a Free Trial
Canada 2470703 ➤ Try a Free Trial
Australia 2002359758 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Federal Trade Commission
Covington
Express Scripts
Baxter
Julphar
McKinsey
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot